Cancer biomarkers are tools used to detect the disease process and monitor the response to therapy in cancer patients. A cancer biomarker refers to any substance or procedure that is characteristic of the existence of cancer in the human body. A biomarker can be a substance secreted by the tumor itself or a general biological response of the human body to the existence of cancer. These substances include serum creatinine, tumor antigens, cytokines, free radicals, chemo markers, DNA methylation, and receptor antigens.
Many cancer biomarkers currently being tested in clinical trials to assess their activity on various cancers. Although these tests are still at an early stage, many exciting results are being seen with each passing day. Moreover, continued advances in cancer diagnosis include the use of molecular biomarkers as part of routine clinical trials. Molecular alterations used for cancer diagnosis involves application of DNA, RNA, microRNAs, and proteins.
Market Dynamics:
Increasing incidence/prevalence of cancer worldwide is expected to fuel the growth of the
cancer biomarkers market. For instance, according to the World Health Organization (WHO), cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths, in 2018.
Moreover, continuous advancements in cancer diagnosis are also expected to augment the growth of the cancer biomarkers market. For instance, in January 2021, biomedical engineers at Duke University devised an algorithm to find new biomarkers and better understand how numerous cancers affect the human body.
Increasing number of collaborations and partnerships and increasing research and development activities are expected to propel the growth of the cancer biomarkers market. For instance, in January 2021, Indian Institute of Technology (Guwahati) signed MoU with North East Cancer Hospital and Research Institute (NECHRI), Assam (India) to identify novel biomarkers for cancer diagnosis, prognosis, therapy, and recurrence.
Increasing use of cancer biomarkers in drug discovery and development and increasing research on cancer biomarkers is also expected to aid the market growth.
North America is expected to witness substantial growth in the cancer biomarkers market due to increasing prevalence of cancer in the region. For instance, according to American Cancer Society, there were likely to be approximately 1,806,590 new cancer cases and 606,520 deaths in the United States in 2020.
Competitive Analysis:
Major players operating in the cancer biomarkers market are Thermo Fisher Scientific Inc., Qiagen N.V., Dickinson and Company, BioMerieux S.A., Merck & Co., Becton, Abbott Laboratories, Bio-Rad Laboratories, and Bard1 Life Sciences Limited.
No comments:
Post a Comment